Legislation & Regulation

AMCP comments on legislation that would increase competition and decrease patients' drug costs.

On July 13, 2018, AMCP provided comments in response to FDA Final Guidance on Payor- Manufacturer communications. AMCP supported the need for timelier and more proactive communications between biopharmaceutical manufacturers and population health decision makers. AMCP applauded the FDA for its leadership and recognition of the importance of modernizing the provisions of the Food and Drug Administration Modernization Act (FDAMA) Section 114 as amended by Section 3037 of the 21st Century Cures Act (Cures) and the creation of a safe harbor for the exchange of preapproval communications.

AMCP participants in sign-on letter from 60 organizations in support of increasing FDA funding for FY 2019.

Press Release: The Academy of Managed Care Pharmacy (AMCP) commends the U.S. Food and Drug Administration (FDA) for issuing final guidance that clarifies how manufacturers can communicate truthful and non-misleading information with payers across a product’s lifecycle.

AMCP letter to Chairman Grassley and Ranking Member Feinstein of the Senate Judiciary Committee

AMCP webinar that detailed the Trump Administration’s American Patients First proposal for addressing the rising cost of pharmaceuticals.

Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, Responds to President Trump’s Speech on Lowering Drug Costs